Result
-€711,789 -€711,789
From profit to loss in 2026, after a profit of €273,324 in 2025.
NEWPHARMA
Lifetime
15 annual accounts with figures on one time axispeak €226.2m (2024)
€218.2m▲ 8.1%
lowest -€1.8m (2020)
-€711,789▼ €985,113
peak €2.5m (2022)
€1.8m▼ 28.3%
€34.4m▲ 40.0%
peak 15.4 FTE (2022)
14.3 FTE▼ 2.1%
Board9 names since 2021
6 directorsGJ LIFESCIENCES MANAGEMENT and 5 others
Owners3 names in the annual accounts
100%NEWPHARMA GROUP
Documentsfilings and deeds
21-09-202640 days before the deadline
2026financial year
Loss of €711,789Equity from €2.5m to €1.8mDebts from €24.6m to €34.4mInvestments €1.9mCash from €5.0m to €1.6m
Key points
from the 2026 annual accountsDebts
€34.4m 94% of the balance sheet
Suppliers 87%Taxes and wages 11%Other 2%
Of this, €33.8m falls due within a year.
Payment terms
50 days to suppliers
NEWPHARMA pays its suppliers 13 days later than in 2025. Customers pay 5 days earlier.
Filings
15 annual accounts since 2011
The 2019 accounts came 14 days late. The other nine of the last ten were filed on time.
Board
1 joined
New director. Latest change 01-08-2026 · 6 in office.
Position in the sector
-€711,789
Lower net result than 95% of companies in retail trade. Sector median €43,673 · 396 companies.
Checked score
68
Healthy
Financially stronger than 19% of small companies in retail trade (NACE 47)
Probability in this band: 0.55% to 1.5%
Bankruptcy probability within 12 months
0.7% Low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.4% across 3,697 companies (NACE 47, small).
About 7 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.3%
01-2025: 0.3%● unchanged vs 12-2024
02-2025: 0.3%● unchanged vs 01-2025
03-2025: 0.3%● unchanged vs 02-2025
04-2025: 0.3%● unchanged vs 03-2025
05-2025: 0.3%● unchanged vs 04-2025
06-2025: 0.3%● unchanged vs 05-2025
07-2025: 0.3%● unchanged vs 06-2025
08-2025: 0.3%● unchanged vs 07-2025
09-2025: 0.3%● unchanged vs 08-2025
10-2025: 0.3%● unchanged vs 09-2025
11-2025: 0.3%● unchanged vs 10-2025
12-2025: 0.3%● unchanged vs 11-2025
01-2026: 0.3%● unchanged vs 12-2025
02-2026: 0.3%● unchanged vs 01-2026
03-2026: 0.3%● unchanged vs 02-2026
04-2026: 0.3%● unchanged vs 03-2026
05-2026: 0.2%▼ -0.1 percentage points vs 04-2026
06-2026: 0.2%● unchanged vs 05-2026
07-2026: 0.2%● unchanged vs 06-2026lowest value
08-2026: 0.2%● unchanged vs 07-2026
09-2026: 0.3%▲ +0.1 percentage points vs 08-2026
10-2026: 0.7%▲ +0.4 percentage points vs 09-2026highest value
11-2026: 0.7%● unchanged vs 10-2026highest value
Financial strengthWeak
Score breakdown
raises risk
Equity €1.8m (4.9% of total assets)
Liquidity: current ratio 1.02, cash €1.6m, halved
Sector: Retail trade (NACE 47)
lowers risk
Size: turnover €218.2m, 14.3 FTE, total assets €36.6m
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, small). It does better than 16% of them on solvency, 5% on liquidity, 12% on profitability and 44% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-03-2026.
Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 912 companies had the same profile as NEWPHARMA has now. Each dot stands for 3 companies, two years later.
95.3%
were still trading
2.1%
stopped another way
2.4%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of NEWPHARMA itself: 0.7% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 912 companies, not a prediction for NEWPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €120,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.02 (1.14 in 2025), below the usual 1.5. Short-term debt is 92.3% and cash 4.5% of total assets. 95.1% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 15% of 399 sector peers (2026).
NBB · sector comparisonPosition among 399 sector peers
Solvency
better than 15%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-03-2026 was due by 31-10-2026 and was filed on 21-09-2026, 40 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2026
40 days early
2025
36 days early
2024
42 days early
2022
26 days early
2021
25 days early
2020
3 days early
2019
14 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 23 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-03-2027 and is due by 31-10-2027. Nothing is late today. The company usually files around 21 September (3 of the last 3 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-03-2027 year end31-10-2027 deadline
Board and ownership
and 1 other
- NEWPHARMA GROUP 100%score 86equity €86.3m (2026) · 31-03-2026 annual accounts of NEWPHARMA GROUP
- SMARTVALUE 99.6%equity €2.4m (2025) · 31-03-2025 annual accounts of SMARTVALUE
Shares in 1 company, Apopharma
Board & ownershipRecent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0838666156
Amendment of the articles · Legal-form change
Legal-form conversion: from private limited company to public limited company · Capital of €5,050,000, 1,000 shares · Gazette deed
4 directors appointed
CASTELEIN, Kris Roger; GOETHAERT, Stefan Annie Willy Maria; VANDAMME, Stefaan Walter Alphons and WILLEMYNS, Jo Paul Maria Agnès Maurits · Gazette deed
Appointment: EY Réviseurs d'Entreprises (statutory auditor)
Permanent representative: Jourquin Gilles · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| NEWPHARMA Liège | €218.2m | -0.4% | 4.9% | 14.3 |
| 123inkt.be Ghent | €63.2m | 2.4% | 20.6% | 39.4 |
| MAKOA Sint-Martens-Latem | €27.5m | 7.5% | 48.5% | 8.2 |
| OPENLANE Belgium Tienen | €32.3m | 9.7% | 85.1% | 30.1 |
| BARQ Dilbeek | €32.6m | 1.8% | 9.4% | 20.6 |
| Pit & Pit Hoogstraten | €20.5m | 7.4% | 24.4% | 8.9 |
| Social Deal België Hasselt | €16.1m | 12.6% | 22.2% | 20.6 |
Grey: the largest companies of the sector (retail trade (NACE 47)), without their names. Blue: the sector peers from the table.
These companies have the same main activity as NEWPHARMA: other non-specialised retail sale (NACE 47120). They are comparable in size and age: total assets between €13m and €33m, founded between 2008 and 2016.
Official details
Source: KBO- Status
- Active since 22-08-2011Normal situation
- Activity
- Other non-specialised retail saleNACE 47120and 1 other
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 31-03-2026
- Establishment units
- 2.202.690.4504020 Liège, since 18-08-2011
- 2.323.998.1554020 Liège, since 01-10-2021
- Financial year end
- 31 March
- Peppol
- Reachable since 03-09-2025
Annual accounts to 31-03-2026
- €36.6m▲ 33.6%
- Employeeson 31-03-2026
- 15=
- Filing
- Filed on 21-09-2026, 40 days before the end of the filing period
Companies linked to NEWPHARMA
Parent and group
Insights on NEWPHARMA
NEWPHARMA has existed since 2011. In 2012 turnover rose from €14,646 to €8.7m and staff from 0.2 to 6.5 full-time equivalents.
NEWPHARMA GROUP holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about NEWPHARMA
- What is the company number of NEWPHARMA?
- The company number of NEWPHARMA is 0838.666.156. The VAT number is the same number with BE in front: BE 0838.666.156.
- Where is NEWPHARMA based?
- The registered office is at Rue Basse-Wez 315/317, 4020 Liège.Company details
- What does NEWPHARMA do?
- According to the KBO register, the main activity is other non-specialised retail sale (NACE 47120).
- What is the legal form of NEWPHARMA?
- NEWPHARMA is a public limited company (NV).
- When was NEWPHARMA founded?
- NEWPHARMA was founded on 22-08-2011.
- Is NEWPHARMA still active?
- Yes, NEWPHARMA is an active enterprise in the KBO register.
- How many employees does NEWPHARMA have?
- NEWPHARMA had an average of 14.3 full-time equivalents in financial year 2026, according to the filed annual accounts.Financials
- Which joint committee does NEWPHARMA fall under?
- In its 31-03-2026 annual accounts, NEWPHARMA states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of NEWPHARMA?
- The turnover of NEWPHARMA was €218.2m in financial year 2026, according to the filed annual accounts.
- Is NEWPHARMA profitable?
- In financial year 2026, NEWPHARMA made a loss of €711,789.
- Where can I find the annual accounts of NEWPHARMA?
- NEWPHARMA filed 15 annual accounts with the National Bank of Belgium, the latest for financial year 2026.
- When are the next annual accounts of NEWPHARMA due?
- NEWPHARMA must file the annual accounts for financial year 2027 by 31-10-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See the other companies in the same group.KORYS · 236 companies
See how customers, suppliers and banks see your own company and what to improve first.